Johnson & Johnson plans to make a whopping $1.5 billion investment in Elan Corp. plc in exchange for a stake in Dublin-based Elan, in a deal that will transfer key Alzheimer's programs, including Phase III bapineuzumab, to the U.S. drugmaker. (BioWorld Today) Read More
